AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 27.83 Million INR | -24.56% |
| 2022 | 36.9 Million INR | -26.49% |
| 2021 | 50.2 Million INR | -41.83% |
| 2020 | 86.3 Million INR | -7.2% |
| 2019 | 93 Million INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | 0.0% |
| 2011 | - INR | 0.0% |
| 2010 | - INR | 0.0% |
| 2009 | - INR | -100.0% |
| 2008 | 625 Million INR | 0.0% |
| 2007 | - INR | 0.0% |
| 2006 | - INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 FY | 27.83 Million INR | -24.56% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 25.78 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 27.83 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 36.9 Million INR | -26.49% |
| 2022 Q4 | 36.9 Million INR | 0.0% |
| 2022 Q2 | 33.88 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 67.08 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 50.2 Million INR | 0.0% |
| 2021 FY | 50.2 Million INR | -41.83% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 89.62 Million INR | 0.0% |
| 2020 Q4 | 86.3 Million INR | 0.0% |
| 2020 FY | 86.3 Million INR | -7.2% |
| 2019 FY | 93 Million INR | 0.0% |
| 2019 Q2 | - INR | 0.0% |
| 2019 Q4 | 93 Million INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2016 Q2 | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2015 Q2 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2015 Q4 | - INR | 0.0% |
| 2014 Q2 | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2014 Q4 | - INR | 0.0% |
| 2013 Q2 | - INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2013 Q4 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2012 FY | - INR | 0.0% |
| 2011 Q4 | - INR | 0.0% |
| 2011 FY | - INR | 0.0% |
| 2010 FY | - INR | 0.0% |
| 2009 FY | - INR | -100.0% |
| 2008 FY | 625 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 95.573% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.87% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 81.142% |
| Granules India Limited | 689.71 Million INR | 95.964% |
| Indoco Remedies Limited | 3.51 Billion INR | 99.209% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 88.165% |
| Alkem Laboratories Limited | 400 Million INR | 93.041% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -680.813% |
| Bajaj HealthCare Limited | 650.34 Million INR | 95.72% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 92.179% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.535% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.575% |
| FDC Limited | 2.46 Million INR | -1028.792% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 98.165% |
| Gufic Biosciences Limited | 1.53 Billion INR | 98.192% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 75.063% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.52% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 63.165% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 98.483% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 99.676% |
| Lupin Limited | 1.55 Billion INR | 98.207% |
| Mankind Pharma Limited | 248.67 Million INR | 88.806% |
| Medicamen Biotech Limited | 12.55 Million INR | -121.712% |
| Medico Remedies Limited | 8.67 Million INR | -220.987% |
| Megasoft Limited | 1.35 Billion INR | 97.949% |
| NATCO Pharma Limited | 53 Million INR | 47.479% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.888% |
| RPG Life Sciences Limited | -30.3 Million INR | 191.868% |
| Sigachi Industries Limited | 265.79 Million INR | 89.527% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -109.293% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 86.892% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 2383.511% |
| Unichem Laboratories Limited | 382.22 Million INR | 92.717% |
| Wanbury Limited | 820 Million INR | 96.605% |
| Windlas Biotech Limited | 20.18 Million INR | -37.939% |
| ZIM Laboratories Limited | 356 Million INR | 92.181% |
| Zydus Lifesciences Limited | 251 Million INR | 88.91% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 73.887% |
| Divi's Laboratories Limited | 20 Million INR | -39.18% |
| Hester Biosciences Limited | 1.81 Billion INR | 98.469% |
| Procter & Gamble Health Limited | 68.8 Million INR | 59.541% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -99.284% |
| Bal Pharma Limited | 363.82 Million INR | 92.349% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.585% |
| Venus Remedies Limited | 386.8 Million INR | 92.804% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -6859.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 98.016% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.503% |
| Aarti Drugs Limited | 2.75 Billion INR | 98.989% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.724% |
| Valiant Laboratories Limited | 746.63 Million INR | 96.272% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 88.225% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 97.37% |
| Themis Medicare Limited | 267.74 Million INR | 89.603% |
| Hikal Limited | 4.22 Billion INR | 99.342% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.826% |
| Sequent Scientific Limited | 1.42 Billion INR | 98.05% |
| Novartis India Limited | 50.7 Million INR | 45.097% |
| Wockhardt Limited | 8.91 Billion INR | 99.688% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.912% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 93.803% |
| Morepen Laboratories Limited | 33.64 Million INR | 17.253% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 79.155% |